Cancer Chemotherapy and Pharmacology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Andrographolide inhibits Burkitt ’s lymphoma by binding JUN and CASP3 proteins
ConclusionAndrographolide inhibits the growth of Burkitt ’s lymphoma by inhibiting JUN and CASP3 proteins. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 26, 2023 Category: Cancer & Oncology Source Type: research

Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report
ConclusionOur patient did not exceed the upper limit of MPA levels as an index of the onset of side effects of kidney transplantation and achieved rapid improvement in liver function. Prompt initiation of MMF after assessment of the steroid effect leads to adequate MPA exposure. Therapeutic drug monitoring should be considered when MMF is administered, to avoid overexposure. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 26, 2023 Category: Cancer & Oncology Source Type: research

Parthenolide inhibits the proliferation and migration of cervical cancer cells via FAK/GSK3 β pathway
ConclusionTaken together, the present in vitro results suggest that PTL may inhibit the proliferation and migration of CC cells through down-regulating the FAK/GSK3 β signaling pathway, providing new insights for the application of PTL in the treatment of CC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 23, 2023 Category: Cancer & Oncology Source Type: research

Retraction Note: Atrial natriuretic peptide protects against cisplatin ‑induced granulocytopenia
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 21, 2023 Category: Cancer & Oncology Source Type: research

Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule
ConclusionThe PK-PD/TD model-based translational approach provides a guide for optimal dose determination to avoid severe PN while maintaining antitumor effects during GnP chemotherapy. Further research is needed to enhance its applicability and potential for combination chemotherapy regimens. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 20, 2023 Category: Cancer & Oncology Source Type: research

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients
ConclusionOur study did not demonstrate a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity. Half of the patients were able to safely continue or restart pazopanib treatment after liver toxicity and received the same dose as prior to drug withdrawal. Successful interventions to address pazopanib-induced toxicity in the clinic led to an algorithm for the management of pazopanib-induced liver toxicity. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 17, 2023 Category: Cancer & Oncology Source Type: research

Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study
ConclusionNo new or unexpected safety concerns were identified, and imaradenant had an acceptable safety profile at both 50- and 75-mg QD.ClinicalTrials.gov identifier NCT03980821 (June 10, 2019). (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 13, 2023 Category: Cancer & Oncology Source Type: research

Enhanced anticancer synergy of LOM612 in combination with selinexor: FOXO1 nuclear translocation-mediated inhibition of Wnt/ β-catenin signaling pathway in breast cancer
ConclusionsCollectively, this study underscores the potential of combining LOM612 and selinexor as an efficacious anti-BC strategy. The underlying mechanism involves FOXO1's nuclear translocation, which disrupts TCF- β-catenin interactions, thus indirectly inhibiting the Wnt/β-catenin signaling pathway. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 5, 2023 Category: Cancer & Oncology Source Type: research

Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer
ConclusionRRM1 may be a potential marker for prognosis and a target marker for gemcitabine resistance in PC. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - December 1, 2023 Category: Cancer & Oncology Source Type: research

Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
ConclusionsThe study results, including a pharmacokinetic profile consistent with weekly dosing and low incidence of immunogenicity, support further investigation of eftozanermin alfa.Trial registration ID: NCT03082209. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 30, 2023 Category: Cancer & Oncology Source Type: research

Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study
ConclusionTEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 28, 2023 Category: Cancer & Oncology Source Type: research

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors
ConclusionIntra-tumoral DNA damage response and inhibition of PARP enzymatic activity were confirmed in patients with advanced solid tumors harboringBRCA1/2 mutations after 8  days of talazoparib treatment. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 27, 2023 Category: Cancer & Oncology Source Type: research

Azithromycin in cancer treatment: envisioning the probable link of mitochondrial dysfunction and necroptosis
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 14, 2023 Category: Cancer & Oncology Source Type: research

Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults
AbstractFedratinib is an oral Janus kinase 2-selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis; however, some patients have difficulty with oral dosing. This randomized, phase 1, open-label, 2-part crossover study evaluated the relative bioavailability, safety, tolerability, taste, and palatability of fedratinib resulting from various alternative oral administration methods in healthy adults. Participants could receive fedratinib 400  mg orally as intact capsules along with a nutritional supplement; as contents of capsules dispersed in a nutritional supplement, delivere...
Source: Cancer Chemotherapy and Pharmacology - November 13, 2023 Category: Cancer & Oncology Source Type: research

Life-threatening toxicities upon Pembrolizumab intake: could pharmacokinetics be the bad guy?
ConclusionThis case report suggests that persistent overexposure in plasma could lead to life-threatening toxicities with Pembrolizumab. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - November 13, 2023 Category: Cancer & Oncology Source Type: research